样式: 排序: IF: - GO 导出 标记为已读
-
Potassium-competitive acid blockers and acid-related disorders. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2024-03-15 Kevin Z Huang, H Christian Weber
Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders.
-
APOC3 siRNA and ASO therapy for dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2024-02-12 Jasmine Chebli, Miriam Larouche, Daniel Gaudet
The aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the therapeutic arsenal for the treatment of lipid disorders and associated risks and to compare the most advanced modalities of apoC3 inhibition currently available or in development, specifically APOC3 antisense oligonucleotides (ASO) and small interfering RNA (siRNA).
-
Bempedoic acid: a new player for statin-intolerant patients and beyond. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-12-15 Salvatore Giordano, Carmen Anna Maria Spaccarotella, Giovanni Esposito, Ciro Indolfi
Low-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease, a condition associated with significant morbidity and mortality. Statins represent the cornerstone for preventing cardiovascular events in patients with elevated LDL-cholesterol (LDL-C) levels, however, they are associated with frequent musculoskeletal adverse effects, which lead to drug discontinuation or limit their use
-
Assessing the contribution of plastic-associated obesogenic compounds to cardiometabolic diseases. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-12-07 Jacob Warger, Michaela Lucas, Andrew Lucas
To present recent evidence that strengthens the concept that exogenous pollutants contribute to adipose dysfunction and increased rates of disease and to highlight the ineffective regulation of this risk as industry switches to related but similarly toxic variants.
-
Endocrine features of primary mitochondrial diseases. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-12-05 Lindsay Romo, Nina B Gold, Melissa A Walker
Primary mitochondrial diseases are one of the most prevalent groups of multisystem genetic disorders. Endocrinopathies associated with mitochondrial diseases may have clinical features that are distinct from the more common forms. We provide an overview of mitochondrial disorder genetics and phenotypes, focusing on recent studies regarding identification and treatment of associated endocrinopathies
-
Legislation, medicine, and politics: care for gender diverse youth. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-11-28 Stephanie Preston, Ximena Lopez
A recent increase in legislation in the United States prohibiting gender-affirming care (GAC) for transgender youth follows a wave of its politicization despite support from all pertinent mainstream medical associations. This review describes the standards of GAC for transgender youth, the origins of legislation prohibiting this care, a review of current legislation in the United States and a discussion
-
Fibrous dysplasia in children and its management. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-11-28 Zubeyir Hasan Gun, Aleena Arif, Alison M Boyce
The purpose of this review is to provide a comprehensive overview into the diagnosis and management of fibrous dysplasia (FD) in children.
-
Bone mass accrual in children. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-11-28 Eugene Rodrick, Joseph M Kindler
Bone accrual during childhood and adolescence is critical for the attainment of peak bone mass and is a major contributing factor towards osteoporosis in later life. Bone mass accrual is influenced by nonmodifiable factors, such as genetics, sex, race, ethnicity, and puberty, as well as modifiable factors, such as physical activity and diet. Recent progress in bone imaging has allowed clinicians and
-
Multifactorial chylomicronemia syndrome. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-11-24 Alan Chait
The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment.
-
Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-11-21 Clara Marquina,Jedidiah I Morton,Zanfina Ademi
PURPOSE OF REVIEW Heterozygous familial hypercholesterolemia (HeFH) is one of the most common monogenic disorders and is safely treatable with lipid-lowering medication. However, most individuals with HeFH remain untreated and undetected, especially in paediatric populations where the potential for long-term therapeutic benefit is higher. Here, we review the recent literature on health economic outcomes
-
Adherence to pharmacotherapy: sine qua non for reducing cumulative risk of premature coronary disease in familial hypercholesterolemia. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-10-31 Jing Pang,Frank M Sanfilippo,Dick C Chan,Gerald F Watts
PURPOSE OF REVIEW Familial hypercholesterolemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to atherosclerotic cardiovascular disease (ASCVD). The risk of ASCVD can be substantially reduced with lipid-lowering treatment (LLT). However, adherence to LLT remains
-
Addressing disparities in technology use among patients with type 1 diabetes: a review. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-10-26 Sarah Kanbour, Estelle Everett
The benefits of continuous glucose monitors (CGMs) and insulin pumps in the management of type 1 diabetes are widely recognized. However, glaring disparities in access exist, particularly in groups that stand to benefit significantly from diabetes technology use. We will review recent data describing drivers of these disparities and approaches to address the disparities.
-
Treating obesity in type 1 diabetes mellitus - review of efficacy and safety. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-10-12 Matthew Freeby, Kyrstin Lane
Obesity is an epidemic in the United States with serious concomitant co-morbid conditions; people living with type 1 diabetes mellitus (T1D) are not immune to the risk either. Weight gain in T1D is likely multifactorial, due to genetic, environmental and treatment-related factors. FDA-approved and other adjunctive weight loss therapies may benefit people living with T1D but there are risks to consider
-
Integrating psychosocial and behavioral interventions into type 1 diabetes care. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-10-07 Elizabeth A Pyatak, Anya R Khurana
To identify recent literature evaluating the efficacy of psychosocial and behavioral interventions for people with type 1 diabetes (T1D).
-
Updates in thyroid healthcare delivery: advancing patient-centered care. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-10-01 Maria Papaleontiou,Megan R Haymart
-
Assisted reproductive technology outcomes and management considerations for people with epilepsy. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-09-21 Regan J Lemley,Paula Emanuela Voinescu
PURPOSE OF REVIEW Epilepsy is a common neurologic condition amongst people with reproductive capacity, and assisted reproductive technology (ART) is being increasingly utilized. A recent population-based study described favorable outcomes of ART in this population, but other work shows how fluctuating sex hormones may influence medication concentrations and seizures. RECENT FINDINGS This review discusses
-
Glucagon-like peptide-1 receptor agonists and safety in the preconception period. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-09-06 Evelyn Minis, Fatima Cody Stanford, Shruthi Mahalingaiah
Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are becoming increasingly popular for the treatment of type II diabetes and obesity. Body mass index (BMI) thresholds at in vitro fertilization (IVF) clinics may further drive the use of these medications before infertility treatment. However, most clinical guidance regarding optimal time to discontinue these medications prior to conception is
-
A review of recent evidence on androgen abuse from interviews with users. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-08-31 Bonnie Grant, Suks Minhas, Channa N Jayasena
Androgens (also known as anabolic-androgenic steroids; AAS) are increasingly being abused worldwide to enhance body physique or athletic performance. Qualitative studies including interviews provide a wider understanding of androgen abuse and focus specific support needs to this group. This narrative review summarizes recent studies (2021-2023) using interviews with individuals abusing androgens.
-
Systematic reviews and meta-analyses on androgen administration in humans: an umbrella review. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-08-22 Razieh Chegeni, Ståle Pallesen, Hailemariam Weldemariam, Dominic Sagoe
The present umbrella review systematically searches and synthesizes recent (2021-2023) systematic reviews and meta-analyses (SRMA) on androgen administration in humans.
-
Surveys on androgen abuse: a review of recent research. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-08-22 Kyle T Ganson, Jason M Nagata
To summarize recent survey research on androgen abuse [i.e., anabolic-androgenic steroids (AAS)], including prevalence among international samples, risk factors for use, associated impairments of use, and treatment and interventions for abusers.
-
Molecular testing for indeterminate thyroid nodules: past, present, and future. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-08-03 Rajam Raghunathan, Stephanie Smooke Praw, Masha Livhits
To examine the origin, current progress, and future directions of molecular testing in indeterminate Bethesda III and Bethesda IV thyroid nodules.
-
Financial toxicity in thyroid cancer survivors. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-07-19 Anastasia K Bogdanovski,Cord Sturgeon,Benjamin C James
PURPOSE OF REVIEW Financial burden and distress are high in patients with thyroid cancer. However, little has been done to evaluate potential interventions to mitigate financial toxicity in survivors. This review will cover current data on the impact of financial toxicity on quality of life and clinical outcomes in patients with thyroid cancer and highlight areas for future study. RECENT FINDINGS Thyroid
-
An update: maternal iodine supplementation, thyroid function tests, and child neurodevelopmental outcomes. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-07-10 Caroline T Nguyen
The impact of maternal iodine supplementation (MIS) during pregnancy on thyroid function and child neurodevelopmental outcomes in areas of mild-to-moderate iodine deficiency (MMID) remains unclear.
-
Obesity and thyroid cancer risk. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-07-07 Lauren C Burrage, Donald S A McLeod, Susan J Jordan
This review explores recent evidence assessing the relationship between obesity and thyroid cancer.
-
Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-07-07 Jenny Eriksrød Skauen, Ståle Pallesen, Astrid Bjørnebekk, Razieh Chegeni, André Syvertsen, Andrea Petróczi, Dominic Sagoe
To investigate the prevalence and correlates of androgen dependence among users. A meta-analysis, meta-regression analysis, and qualitative synthesis were conducted based on a systematic literature search in Google Scholar, ISO Web of Science, PsycNET, and PubMed.
-
Recent advances in anaplastic thyroid cancer management. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-07-07 Sarah Hamidi, Anastasios Maniakas
To summarize recent developments in the diagnosis and management of patients with anaplastic thyroid cancer (ATC).
-
Novel techniques for assessment of bone tissue material properties. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-21 Ajay D Rao
PURPOSE OF REVIEW The purpose of this review will be to shed light on novel techniques for assessment of bone tissue material properties. RECENT FINDINGS Recently there has been an increase in modalities to investigate bone tissue material properties. Historically, clinicians treating patients with bone disorders have relied upon the use of bone mineral density (BMD) as assessed by dual-energy X-ray
-
MR-based techniques for intracortical vessel visualization and characterization: understanding the impact of microvascular disease on skeletal health. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-20 Maximilian T Löffler, Po-Hung Wu, Galateia J Kazakia
The relationships between bone vasculature and bone microstructure and strength remain incompletely understood. Addressing this gap will require in vivo imaging capabilities. We describe the relevant vascular anatomy of compact bone, review current magnetic resonance imaging (MRI)-based techniques that allow in vivo assessment of intracortical vasculature, and finally present preliminary studies that
-
Effect of incretins on skeletal health. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-13 Jakob Starup-Linde, Katrine Hygum, Bente Langdahl
The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health.
-
Overuse of thyroid ultrasound. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-09 Gonzalo J Acosta, Naykky Singh Ospina, Juan P Brito
Thyroid ultrasound (TUS) is a common diagnostic test that can help guide the management of patients with thyroid conditions. Yet, inappropriate use of TUS can lead to harmful unintended consequences. This review aims to describe trends in the use and appropriateness of TUS in practice, drivers and consequences of inappropriate use, and potential solutions to decrease overuse.
-
The psychosocial impact of thyroid cancer. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-09 Parker Haymart, Nina Jackson Levin, Megan R Haymart
This review discusses the psychosocial impact of thyroid cancer diagnosis and management. It summarizes recent findings, presents management options, and briefly discusses future directions.
-
Cardiovascular outcomes in subclinical thyroid disease: an update. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-06-09 Matthew D Ettleson
Subclinical thyroid disease is defined by a thyroid stimulating hormone (TSH) level outside of the normal range with normal circulating thyroid hormone levels. Excess adverse cardiovascular outcomes have been observed in certain patient populations with subclinical hypothyroidism (SCH) and hyperthyroidism (SCHr). The role of thyroid hormone and antithyroid treatments for subclinical thyroid disease
-
Effects of very low carbohydrate ketogenic diets on skeletal health. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-05-03 Cora M Best, Simon Hsu
Very low carbohydrate ketogenic diet (KD) therapy has been associated with skeletal demineralization in children with drug-resistant epilepsy, but the cause of this association is unclear. Recently, interest in the KD has grown owing to its potential benefits for other illnesses including cancer, type 2 diabetes, obesity, and polycystic kidney disease. Summaries of the best available evidence regarding
-
Molecular tools for diagnosing diseases of the adrenal cortex Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-17 Fabio R. Faucz, Andrea G. Maria, Constantine A. Stratakis
Purpose of review The adrenal glands produce some of the most essential for life hormones, including cortisol and other steroids, and catecholamines. The former is produced from the adrenal cortex, whereas the latter is from the medulla. The two parts are anatomically and functionally distinct and it would be impossible in the context of one short article to cover all molecular updates on both the
-
Surgical approaches to the adrenal gland Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-14 Alaa Sada, Travis J. McKenzie
Purpose of review Review the literature on the surgical management of adrenal diseases, highlighting the various surgical approaches and their respective pros and cons. Recent findings Minimally invasive adrenalectomy is commonly used for small and benign adrenal tumors, whereas open adrenalectomy is preferred for larger tumors and primary adrenal malignancy. Although minimally invasive adrenalectomy
-
Diagnostic strategies in adrenal insufficiency Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-07 Vasiliki Siampanopoulou, Elisavet Tasouli, Anna Angelousi
Purpose of review Adrenal insufficiency (AI) is the clinical manifestation of deficient production of glucocorticoids with occasionally deficiency also in mineralocorticoids and adrenal androgens and constitutes a fatal disorder if left untreated. The aim of this review is to summarize the new trends in diagnostic methods used for determining the presence of AI. Recent findings Novel aetiologies
-
Biomarkers in gastroenteropancreatic neuroendocrine neoplasms Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-03-09 Isa Mulingbayan Jacoba, H. Christian Weber
Purpose of review Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) represent a heterogenous group of rare tumors emanating from neuroendocrine cells that are clinically silent for prolonged periods of time without detection. Traditional biomarkers lack sufficiently high enough specificity and sensitivity for these tumors and their secreted products. New molecules are sought to improve accuracy
-
Glucocorticoid withdrawal syndrome: what to expect and how to manage Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-03-06 Verena Theiler-Schwetz, Alessandro Prete
Purpose of review Glucocorticoid withdrawal syndrome (GWS) can develop after withdrawing exposure to supraphysiological levels of endogenous or exogenous glucocorticoids due to an established physical dependence. It is characterised by symptoms similar to adrenal insufficiency but needs to be regarded as a separate entity. GWS is often under-recognised in clinical practice and affected patients can
-
Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Ty E. Sweeney, Sean P. Gaine, Erin D. Michos
Purpose of review Populations with greater fatty fish intake have lower risk of coronary heart disease. However, trials testing omega-3 fatty acids (FA) on cardiovascular outcomes have yielded inconsistent results. In this review, we summarize the major cardiovascular trials examining omega-3 FA supplementation, and compare differences with eicosapentaenoic acid (EPA) alone vs. docosahexaenoic acid
-
Xenosterolemia in clinical practice: what is in a name? Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Wann Jia Loh, Gerald F. Watts
Purpose of review The aim of this study was to assess the potential value of the measurement of plasma xenosterols (or phytosterols) concentrations in clinical practice. Recent findings Recent genetic studies suggest that individuals with elevated plasma phytosterol concentrations due to monogenic and polygenic variants are at an increased risk of coronary artery disease. This supports early observations
-
What is really new in triglyceride guidelines? Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Aliza Hussain, Mahmoud Al Rifai, Melody Hermel, Leandro Slipczuk, Salim S. Virani
Purpose of review In this review, we will summarize some of the landmark clinical trials of triglyceride-lowering therapies and review updates in clinical guidelines with regards to treatment of elevated triglyceride levels. Recent findings Accumulating evidence from epidemiologic and Mendelian randomization studies has shown that triglyceride and are causally linked to atherosclerotic cardiovascular
-
Cardiovascular disease in metabolic-associated fatty liver disease Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Leon A. Adams
Purpose of review Fatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease (CVD). Recent findings This review describes the cardiovascular outcomes, clinical assessment and management as well as the impact of emerging drug treatment on CVD risk. Summary Patients with fatty liver require CVD risk assessment including consideration of
-
Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Wann Jia Loh, Gerald F. Watts
Purpose of review Elevated Lp(a) level is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD), principally coronary artery disease. Selective testing for Lp(a) is highly recommended in patients at intermediate and high risk for ASCVD. Lp(a) levels are predominantly genetically determined, and this has implications for cascade testing. Recent findings Recent studies
-
Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Nick S.R. Lan, Damon A. Bell, Gerald F. Watts, P. Gerry Fegan
Purpose of review Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality in adults with type 1 diabetes (T1D). Although dyslipidaemia is a modifiable and prevalent risk factor in individuals with T1D, determining when to initiate lipid-lowering therapy for primary prevention of ASCVD can be challenging. In this article, recommendations for lipid-lowering therapy from updated
-
Low-carbohydrate diets in type 1 diabetes: balancing benefits and risks Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Michael Hancock, Kharis Burns, Seng Khee Gan, Gerard T. Chew
Purpose of review Interest in the use of calorie restriction with low-carbohydrate diets for patients with type 1 diabetes appears to be increasing despite physicians’ discomfort about its longer term outcomes. A divergence in opinion regarding the balance of benefits and safety may lead to patient disengagement from conventional medical supervision. This review describes the current evidence regarding
-
Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease? Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Takahito Doi, Børge G. Nordestgaard, Anne Langsted
Purpose of review To summarize recent studies analyzing reclassification of estimated risk of myocardial infarction (MI) and ischemic heart disease (IHD) by inclusion of remnant cholesterol (= cholesterol content in triglyceride-rich lipoproteins) in primary and secondary prevention settings. Recent findings For individuals in a primary prevention setting with remnant cholesterol levels at least
-
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-04-01 Christine M. Trapp, Marisa Censani
Purpose of review Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. Recent findings Between February 2017 and September 2018, 10 participants with pro-opiomelanocortin (POMC)/ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and 11 participants with leptin receptor (LEPR) deficiency were enrolled in open-label, phase 3 trials at
-
Diabetes mellitus in Bardet Biedl syndrome Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Jeremy Pomeroy, Kelsi-Marie Offenwanger, Tammi Timmler
Purpose of review Bardet Biedl syndrome (BBS) is a rare disease characterized by obesity and hyperphagia. Despite the very high prevalence of paediatric and adult obesity in this population, the prevalence of diabetes mellitus is not well described. Recent findings Studies in small and moderately large cohorts suggest a high prevalence of traditional risk factors for diabetes mellitus in people with
-
Editorial: Childhood endocrine and genetic disorders: improving adult outcomes. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Lynne L Levitsky
-
Facilitating the transition from paediatric to adult care in endocrinology: a focus on growth disorders Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Janaki D. Vakharia, Takara L. Stanley
Purpose of review Many childhood-onset growth disorders (COGDs) require continued care into adulthood, and the time of transition between paediatric and adult providers carries a high risk for interruptions in medical care and consequent worsening of disease management. Recent findings Research into best practices for healthcare transition (HCT) describes three distinct stages. Stage 1, transition
-
Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed? Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Natasha Prakash Malkani, Vanita R. Aroda
Purpose of review Glucose-lowering medications have become strong choices for purposes beyond glucose control in both patients with and without type 2 diabetes. Recent studies have explored the use of specific glucose-lowering therapies in areas such as cardiovascular disease, renal disease, obesity, nonalcoholic fatty liver disease (NAFLD), and Alzheimer's disease, among others. This begs the question
-
Type 2 diabetes mellitus and cognitive function: understanding the connections Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Lisa Dao, Sarah Choi, Matthew Freeby
Purpose of review To review the connection between type 2 diabetes and cognitive dysfunction, including its epidemiology, potential mechanisms of pathophysiology, risk factors, possible prevention, and treatment considerations. Recent findings Diabetes is a risk factor for mild cognitive decline, in addition to Alzheimer's disease and vascular dementia. Duration of diabetes, concomitant vascular
-
Turner syndrome: fertility counselling in childhood and through the reproductive lifespan Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Kassie J. Bollig, Monica Mainigi, Suneeta Senapati, Angela E. Lin, Lynne L. Levitsky, Vaneeta Bamba
Purpose of review The potential for fertility in Turner syndrome has improved in recent years. Understanding of associated risks and approaches is important for the care of girls and women with this condition. This review focuses on reproductive health, fertility options and appropriate counselling for women with Turner syndrome and their families. Recent findings Women with Turner syndrome have
-
An update on the diagnosis and treatment of adrenoleukodystrophy Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Jasmine Gujral, Swathi Sethuram
Purpose of review The present review summarizes recent advances in the diagnosis and management of patients with X-linked adrenoleukodystrophy (ALD). Recent findings Although ALD screening has been on the list of Recommended Uniform Screening Panel since 2016, only 30 states in the United States are currently testing their newborns for this disease. Hematopoietic stem cell transplant (HSCT) remains
-
Update on management of paediatric dyslipidaemia Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Nidhi Bansal, Seema Kumar, Preneet Cheema Brar
Purpose of review Atherosclerosis and associated cardiovascular risk factors originate in childhood; hence, early management of dyslipidaemia is vital. However, hypercholesterolemia remains untreated or undertreated in many youths. We review current therapies, drugs under investigation and consider potential future directions for the management of paediatric dyslipidaemia to highlight the recent evidence
-
A short history of saturated fat: the making and unmaking of a scientific consensus Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2023-02-01 Nina Teicholz
Purpose of review This article recounts the history of the diet-heart hypothesis from the late 1950s up to the current day, with revelations that have never before been published in the scientific literature. Insights include the role of authorities in launching the diet-hypothesis, including a potential conflict of interest for the American Heart Association; a number of crucial details regarding
-
Editorial: Health considerations across the lifespan for patients with polycystic ovary syndrome. Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2022-12-01 Shruthi Mahalingaiah
-
Better care for women with polycystic ovary syndrome – a proposal for an international evidence based best practice framework to improve care Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2022-12-01 Chau Thien Tay, Anju E. Joham, Lisa J. Moran, Helena Teede
Purpose of review Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-age women and has reproductive, pregnancy, metabolic, dermatologic, and psychologic complications. Here we summarize current challenges and gaps in PCOS care, and propose a pathway forward to implement high quality international guideline recommendations and resources, through development of a best
-
Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2022-12-01 Daryl J. Selen, Camille E. Powe
Purpose of review This review provides an update on gestational diabetes (GDM) and other adverse pregnancy outcomes in individuals with polycystic ovary syndrome (PCOS), one of the most common metabolic disorders and causes of infertility. Recent findings Recent studies using Rotterdam diagnostic criteria for PCOS have supported prior literature suggesting that pregnant individuals with PCOS are
-
Use of anti-Müllerian hormone for understanding ovulatory dysfunction in polycystic ovarian syndrome Curr. Opin. Endocrinol. Diabetes Obes. (IF 3.2) Pub Date : 2022-12-01 Begum Aydogan Mathyk, Esra Cetin, Bulent O. Yildiz
Purpose of review The aim of this review is to understand how anti-Müllerian hormone (AMH) contributes to ovulatory dysfunction in polycystic ovarian syndrome (PCOS). Recent findings In the last few years, new findings have emerged on AMH and its role on the central nervous system causing ovulatory dysfunction. Summary Anovulation is a prominent feature of PCOS. Women with anovulatory PCOS have